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Abstract
Background: Targeting the TGF-β1 pathway for breast cancer metastasis therapy has become an attractive strategy.
We have previously demonstrated that naringenin significantly reduced TGF-β1 levels in bleomycin-induced lung
fibrosis and effectively prevented pulmonary metastases of tumors. This raised the question of whether naringenin can
block TGF-β1 secretion from breast cancer cells and inhibit their pulmonary metastasis.
Methods: We transduced a lentiviral vector encoding the mouse Tgf-β1 gene into mouse breast carcinoma
(4T1-Luc2) cells and inoculated the transformant cells (4T1/TGF-β1) into the fourth primary fat pat of Balb/c
mice. Pulmonary metastases derived from the primary tumors were monitored using bioluminescent imaging.
Spleens, lungs and serum (n = 18–20 per treatment group) were analyzed for immune cell activity and TGF-β1
level. The mechanism whereby naringenin decreases TGF-β1 secretion from breast cancer cells was investigated at
different levels, including Tgf-β1 transcription, mRNA stability, translation, and extracellular release.
Results: In contrast to the null-vector control (4T1/RFP) tumors, extensive pulmonary metastases derived from
4T1/TGF-β1 tumors were observed. Administration of the TGF-β1 blocking antibody 1D11 or naringenin showed an
inhibition of pulmonary metastasis for both 4T1/TGF-β1 tumors and 4T1/RFP tumors, resulting in increased survival of
the mice. Compared with 4T1/RFP bearing mice, systemic immunosuppression in 4T1/TGF-β1 bearing mice was
observed, represented by a higher proportion of regulatory T cells and myeloid-derived suppressor cells and a lower
proportion of activated T cells and INFγ expression in CD8+ T cells. These metrics were improved by administration of
1D11 or naringenin. However, compared with 1D11, which neutralized secreted TGF-β1 but did not affect intracellular
TGF-β1 levels, naringenin reduced the secretion of TGF-β1 from the cells, leading to an accumulation of intracellular
TGF-β1. Further experiments revealed that naringenin had no effect on Tgf-β1 transcription, mRNA decay or protein
translation, but prevented TGF-β1 transport from the trans-Golgi network by inhibiting PKC activity.
Conclusions: Naringenin blocks TGF-β1 trafficking from the trans-Golgi network by suppressing PKC activity, resulting
in a reduction of TGF-β1 secretion from breast cancer cells. This finding suggests that naringenin may be an attractive
therapeutic candidate for TGF-β1 related diseases.
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Background
Breast cancer is the most common malignancy in female
cancer patients, accounting for 23 % of all new cancer
cases worldwide. Metastasis from the primary breast
tumor is the leading cause of mortality among these pa-
tients [1, 2]. An association between elevated cellular
and plasma transforming growth factor (TGF)-β1 levels
and increased breast cancer metastasis has been re-
ported previously [3–7]. Secreted TGF-β1 promotes me-
tastasis via transforming T cells to regulatory T cells
(Tregs), which facilitates the escape of cancer cells from
host immune responses [8], and/or by inducing cancer
cells to undergo epithelial to mesenchymal transition
(EMT) [9]. The proliferation of cancer cells increases
TGF-β1 secretion, leading to a more metastatic pheno-
type [10]. Clinical studies have reported a link between
the presence of a tumor and an increase of CD4+CD25+
cells in the blood [11–13]. Tregs constitutively express
Foxp3, which is the master regulator that mediates the
immunosuppressive function of Tregs [14–16].
Small molecule TGF-β1 inhibitors are a feasible ap-
proach for breast cancer metastasis prevention and ther-
apy. TGF-β1 blocking antibodies, short hairpin RNA of
TGF-β1, and inhibitors of TGF-β1 receptors have been
shown to prevent tumor development and metastasis
[17–19]. However, complete inhibition of TGF-β1 signal-
ing by receptor inhibitors or antibodies showed serious
adverse effects, such as gastrointestinal and skin-related
events [20], thrombocytopenia, and keratoacanthomas/
squamous cell carcinoma [21].
TGF-β proteins are synthesized as inactive precursor
proteins with an amino-terminal prodomain followed by
the carboxyl-terminal mature ligand. Precursor proteins
dimerize in the endoplasmic reticulum (ER), where they
are cleaved by serine proteases. Following processing,
they are transported through the trans-Golgi network
(TGN) to the cell surface for release and to the lysosome
for degradation [22–24]. Inhibiting the proteins that tar-
get TGF-β for secretion may be a new strategy to block
signal transduction of the TGF-β pathway.
Naringenin, the predominant flavanone in grapefruit,
is reported to possess a broad range of pharmacological
activities, such as antioxidant, anti-inflammatory, carbo-
hydrate metabolism promotion, and modulating the im-
mune system [25]. Our previous study showed that
naringenin reduced TGF-β1 levels in fibrotic microenvi-
ronments and prevented fibrosis-induced lung metasta-
sis [26], and that naringenin inhibited TGF-β1-induced
migration and invasion of pancreatic cancer cells [27]. In
the context of fibrosis-induced lung metastasis, TGF-β1
could be derived from various cell types, including can-
cer cells, fibroblasts, macrophages, epithelial cells, and
immune cells. To investigate the role of breast tumor-
derived TGF-β1 for metastasis, and whether naringenin
can suppress metastasis by blocking TGF-β1 secretion
from breast tumor cells, we constructed a Tgf-β1 over-
expressing breast tumor cell line (4T1/TGF-β1) and
examined its metastatic potential in both in vitro and
in vivo models. Our data demonstrated that naringenin ef-
fectively reduced TGF-β1 release and suppressed tumor
cell migration and pulmonary metastasis. Unexpect-
edly, naringenin prevented TGF-β1 secretion by a
post-translational mechanism, which differs from
TGF-β neutralizing antibodies and TGF-β receptor
antagonists. The results of this study may provide a
novel therapeutic approach for intervention of TGF-β
signaling pathway-related diseases and disorders.
More importantly, our study reveals that targeting the
intracellular trafficking machinery of cytokines may be
an attractive strategy for developing new anti-cytokine
therapies.
Methods
Cell lines and materials
The murine breast cancer cell line 4T1 was purchased
from American Type Culture Collection (Manassas, VA,
USA). 4T1 cells, the vector control (4T1/RFP), and
TGF-β1-overexpressing 4T1-Luc2 cells (4T1/TGF-β1)
were cultured in RPMI 1640 medium. 1D11 antibody
was from eBioscience Tech (San Diego, CA, USA).
Naringenin was purchased from Shanxi Huike Botanical
Development Co. (Xi'an, China).
Generation of 4T1/TGF-β1 transformants
Human growth hormone signal sequence was synthe-
sized and fused with the full-length mouse Tgf-β1 gene
using PCR. The hybrid gene of human growth hormone
signal sequence and mouse Tgf-β1 was then ligated into
pSin-EF2-Oct4-Pur plasmid (Addgene, Cambridge, MA,
USA) to replace Oct4 with SpeI and EcoRI cloning
sites at the 5′ and 3′ termini, respectively. RFP from
the pmRFP-C1 plasmid (Clontech, Mountain View,
CA, USA) was then cloned into the pSin-EF2-
TGFβ1-Pur plasmid to replace puromycin. The gen-
erated Tgf-β1 overexpression vectors were then
enveloped in 293T cells. The medium containing the
packaged virus was used to infect 4T1-Luc2 breast
cancer cells (PerkinElmer, Waltham, MA, USA) to
generate 4T1/TGF-β1 transformants. The control
transformants, 4T1/RFP cells, were generated using
the vector without Tgf-β1 gene, following the same
procedures. 4T1/RFP and 4T1/TGF-β1 transformants
were then sorted by flow cytometry with excitation/
emission of 578/603 nm.
In vivo breast cancer metastasis experiments
Four-week-old female Balb/c mice were purchased from
Weitonglihua Tech. (Beijing, China) and housed in the
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Animal Care Facility of the Institute of Biophysics, Chinese
Academy of Sciences, China. All animal protocols used for
this study were approved by the Institutional Animal
Care and Use Committee. The fourth mammary fat
pads of Balb/c mice were injected with 2 × 104 4T1/RFP
or 4T1/TGF-β1 cells. Beginning on the same day, the mice
were administered 200 mg/kg naringenin once daily for
30 days (suspension in 1 % sodium carboxyl methyl cellu-
lose (CMCNa)) or 5 mg/kg 1D11 antibody (dilution in
phosphate-buffered saline buffer) twice a week for 3 weeks.
The primary tumor and lung metastases were imaged
by bioluminescence using the IVIS Spectrum In Vivo
Imaging System (Xenogen, Caliper Life Science, PerkinEl-
mer, Hopkinton, MA, USA ) as described previously [28].
Briefly, tumor-bearing mice were given intraperitoneal in-
jections with 150 mg/kg luciferin and the lung areas were
imaged. To avoid the bioluminescence from the primary
tumor, primary tumors were wrapped with light-proof
bags. After 4 weeks of primary tumor growth, mice were
sacrificed after intraperitoneal injection of luciferin for
15 minutes and the lungs were collected for imaging or
weighing to determine the amount of metastases. The
weight of tumor burden in the lung was calculated by sub-
tracting the mean weight of normal lungs (0.15 g) from
the weight of the lungs with metastatic tumors; primary
tumors were also isolated and weighted. After treatment,
the lungs and spleens of each mouse at day 14 and day 28
were dissected for quantitative PCR (qPCR), T-cell im-
munity assays, and immunohistochemistry. The levels of
activated TGF-β1 in the primary tumors, spleens, lungs,
and serum were detected by enzyme-linked immunosorb-
ent assay (ELISA). The bioluminescence imaging, qPCR
[29], T-cell immunity assays, immunohistochemistry, and
TGF-β1 ELISA were performed as described previously
[26] (details in Additional file 1). The survival endpoint of
mice was defined as the day of the mouse’s death.
T-cell activity assays
In vivo assays of T-cell activation were performed as
described previously [26]. Briefly, isolated lymphocytes
from the spleen and lung were surface-stained with
fluorochrome-conjugated anti-CD4, anti-CD44, and
anti-CD62L antibodies. To assay myeloid-derived sup-
pressor cells (MDSC), isolated splenocytes or purified T
cells from the lungs were stained with fluorochrome-
conjugated anti-Gr-1 and anti-CD11b antibodies. To
analyze the production of interferon gamma (IFNγ) in
CD8+ T cells, isolated splenocytes were stimulated with
25 ng/ml phorbol 12-myristate 13-acetate (Sigma, St.
Louis, MO, USA) and 500 ng/ml ionomycin (Sigma) for
5 hours. After further incubation with Brefeldin A Solu-
tion (eBioscience) for 3 hours, the stimulated cells were
surface-stained with anti-CD8 antibodies, fixed and
permeabilized, and then stained with anti-IFNγ antibody.
For Treg assays, the isolated splenocytes or purified T
cells from lungs were separated using CD4 MACS beads
(Miltenyi Biotec, Cologne, Germany). The separated
CD4+ T cells were cultured in the supernatants with
anti-CD3 antibody (3 μg/ml) and anti-CD28 antibody
(1 μg/ml) for 72 hours. The cells were surface-stained
with anti-CD4 and anti-CD25 antibodies, fixed and
permeabilized, and then stained with anti-Foxp3 anti-
body. The stained cells were analyzed by flow cytometry
using a FACSCalibur system with CellQuest software
(BD Biosciences, San Jose, CA, USA).
Transfer of T cells and 4T1/TGF-β1 cancer cells into nude
mice
T cells were isolated from the spleen of normal (control
group) or 4T1/TGF-β1 tumor-bearing Balb/c mice with
naringenin or 1 % CMCNa treatment. After red blood
cells were lysed by ACK hypotonic lysis solution
(Sigma), T cells were purified using a pan T-cell isola-
tion kit (Miltenyi Biotech) in accordance with the man-
ufacturer’s protocol. Balb/c nude mice were then
intravenously injected with 5 × 105 of these purified T
cells mixed with 5 × 103 4T1/TGF-β1 tumor cells
(100:1 ratio of T cells to 4T1/TGF-β1 tumor cells). T
cells with tumor cells were transferred once a week for
3 weeks. The transfer of the mixed cells to nude mice
was performed as described previously [30]. The bio-
luminescence of lung metastasis in nude mice on day
28 was imaged using the IVIS system as described pre-
viously [28] (details in Additional file 1).
Confocal imaging
Cellular localization of TGF-β1 in 4T1 cells with different
treatments was determined by immunofluorescence
staining with Alexa 633-labeled secondary IgG antibody
after anti-TGF-β1 antibody binding. The TGN was stained
with Alexa 488-labeled secondary IgG antibody after
anti-TGN46 antibody binding. The nuclei were stained
with Hoechst 33342. Stained cells were observed using
confocal microscopy as described [31] previously (details
in Additional file 1).
Statistical analysis
All in vivo experiments included at least five mice per
group. Results are presented as median ± interquartile
(IQ) range or median ± standard error (SE). Analysis of
results containing two groups was carried out using
the Student t test, assuming unequal variance. Two-
way analysis of variance was performed to determine
the variations of bioluminescent photons between the
control and TGF-β1 overexpression groups. The sur-
vival curves were analyzed using log-rank (Mantel–
Cox test) analysis. P <0.05 was considered statistically
significant.
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Results
TGF-β1 overproduction in 4T1 tumor cells promotes
pulmonary metastasis
To investigate the role of TGF-β1 overexpression in 4T1
cells in pulmonary metastasis, we constructed a lentiviral
vector that expressed a hybrid construct containing
human growth hormone signal sequence and murine
Tgf-β1, which enabled the transduced cells to secrete ma-
ture TGF-β1 (4T1/TGF-β1). Compared with the null-
vector control cells (4T1/RFP), 4T1/TGF-β1 cells showed
increased expression of Tgf-β1 mRNA (2332-fold increase;
P <0.001), as well as increased cellular and secreted TGF-
β1 (P = 0.05 and P = 0.01, respectively) (Fig. 1a, b). The
4T1/TGF-β1 cells also showed increased migration and
invasion compared with 4T1/RFP cells in vitro (Fig. 1c).
However, cellular invasion of both 4T1/RFP and 4T1/
TGF-β1 was inhibited by addition of TGF-β1 neutralizing
antibody (1D11) to the medium (Fig. 1c). Furthermore, we
quantitated TGF-β1 secretion in several human breast
cancer cell lines, and found that secreted TGF-β1 levels
were positively related to invasiveness of the cancer cells
(Additional file 2: Figure S1).
We next investigated whether Tgf-β1 overexpression led
to extensive pulmonary metastases. 4T1/TGF-β1 cells and
4T1/RFP cells were injected into the fourth breast pads of
mice, and pulmonary metastases were determined at day
28 after injection. The bioluminescence images showed that
all of the mice bearing 4T1/TGF-β1 tumors had pulmonary
metastases with brighter bioluminescence than the mice
bearing 4T1/RFP tumors, in which only one mouse had de-
tectable bioluminescence before the dissected lungs were
exposed (for the in vivo lung imaging, P = 0.023; for the dis-
sected lung imaging, P = 0.006) (Fig. 1d, e). The histological
sections of lungs from mice bearing 4T1/TGF-β1 tumors
showed larger metastatic lesions than those from mice
bearing 4T1/RFP tumors (Fig. 1f). The tumor burden
weight in removed lungs from mice bearing 4T1/TGF-β1
tumors was greater than that of lungs from mice bearing
4T1/RFP tumors (P <0.001) (Fig. 1h), while the tumor
weight at the primary site did not show a significant
difference between the mice bearing 4T1/RFP cells
and the mice bearing 4T1/TGF-β1 cells (P = 0.43) (Fig. 1g
and Additional file 3: Figure S2). The extensive pulmonary
metastases in the 4T1/TGF-β1 tumor-bearing mice could
lead to a decreased life span. Indeed, the survival analysis
showed that all of the 4T1/TGF-β1 tumor-bearing mice
without any treatment died at day 45 after tumor cell injec-
tion, while the 4T1/RFP tumor-bearing mice without treat-
ment displayed an increased life span (P = 0.007) (Fig. 2c).
Naringenin inhibits pulmonary metastasis from the
primary breast tumor
As shown in Fig. 2, naringenin administration had an in-
hibitory effect on pulmonary metastasis at day 34 (similar
inhibitory effects on pulmonary metastasis at day 24
shown in Additional file 3: Figure S2A) and prolonged
survival to levels comparable with 1D11 antibody admin-
istration in 4T1/TGF-β1 tumor-bearing mice, but better
than 1D11 in 4T1/RFP tumor-bearing mice (for survival
in 4T1/RFP: naringenin vs control, P = 0.032 and 1D11 vs
control, P = 0.19; for survival in 4T1/TGF-β1: naringenin
vs control, P = 0.012 and 1D11 vs control, P = 0.021)
(Fig. 2a–c). In contrast to the untreated control, narin-
genin and 1D11 treatments decreased the incidence of
pulmonary metastasis in tumor-bearing mice on day 24
and day 34 (for 4T1/TGF-β1 tumor-bearing mice on day
24: 57 % (4/7) in control group, 14 % (1/7) in naringenin
group, and 29 % (2/7) in 1D11 group; for 4T1/RFP tumor-
bearing mice on day 34: 100 % (7/7) in control group,
29 % (2/7) in naringenin group, and 43 % (3/7) in 1D11
group) (Additional file 4: Table S1). The growth of the pri-
mary tumor was not significantly affected by naringenin
treatment or by 1D11 treatment compared with the un-
treated control mice (Additional file 3: Figure S2B, C).
The reduction of pulmonary metastasis by naringenin and
1D11 treatments could result from lower levels of acti-
vated TGF-β1 circulating in the serum of tumor-bearing
mice. Therefore, we determined the levels of the activated
TGF-β1 in the serum and in the lung on day 34. Com-
pared with normal mice, the activated TGF-β1 concentra-
tion in lung tissues and circulating serum was significantly
elevated both in 4T1/RFP and 4T1/TGF-β1 tumor-
bearing mice. As expected, naringenin and 1D11 treat-
ments reduced active TGF-β1 levels both in the lung and
serum (Fig. 2d).
To ascertain the role of tumor-secreted TGF-β1 in
promoting pulmonary metastasis, we determined levels
of the activated form of TGF-β1 in the tumor, spleen,
lung, and serum on days 14 and 28 after tumor cell
implantation. Activated TGF-β1 was increased in all sam-
ples, including tumor, lung, and serum from tumor-
bearing mice compared with tumor-free mice (P <0.05).
Naringenin treatment significantly reduced activated
TGF-β1 levels in the tissues and serum in tumor-bearing
mice (P <0.05) (Additional file 5: Figure S3A, B). Tumor-
derived TGF-β1 has been showed to induce the expres-
sion of Foxp3, which is a firm link between TGF-β1 levels
and Tregs [32, 33]. In agreement with these studies,
an increase of Foxp3 expression was observed in the lungs
of tumor-bearing mice, particularly in mice bearing 4T1/
TGF-β1 tumors. Naringenin administration reduced
Foxp3 expression in the lungs of tumor-bearing mice
(Additional file 5: Figure S3D). The immunohistochemical
images of the lungs on day 14 and day 28 after tumor in-
jection showed a histologic disruption of lung structure
and an increase of TGF-β1 staining. Naringenin treatment
decreased TGF-β1 staining and restored normal lung
architecture (Additional file 5: Figure S3C).
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Fig. 1 (See legend on next page.)
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Naringenin modulates the immunosuppressive
environment in tumor-bearing mice
The elevated TGF-β1 levels were accompanied by in-
creased Foxp3 expression in the lungs of 4T1/TGF-β1
tumor-bearing mice, which aroused our interest in the
relationship between TGF-β1 production and the Treg
population. Because previous studies have revealed that
tumor-derived TGF-β1 mediates the conversion of
CD4+Foxp3+ Tregs [34], we measured the percentage
of CD4+CD25+Foxp3+ Tregs and CD103+CD4+Foxp3+
cells in lymphocytes from the spleens and lungs of tumor-
bearing mice. The expression of CD103 in lymphoid
CD4+Foxp3+ cells was reported to recruit Tregs into tumor
sites [35]. Overproduction of TGF-β1 in 4T1/TGF-β1
tumor-bearing mice was associated with a higher percent-
age of CD4+CD25+Foxp3+ cells in the lungs and CD103
+CD4+Foxp3+ cells in the spleens, compared with 4T1/RFP
tumor-bearing mice and tumor-free mice. Both naringenin
and 1D11 treatments significantly reduced the percentage
of CD4+CD25+Foxp3+ and CD103+CD4+Foxp3+ cells in
the lungs and spleens, respectively, of 4T1/TGF-β1 tumor-
bearing mice (P <0.05) (Fig. 3a, b).
Several studies have indicated that TGF-β1 can induce
an immunosuppressive microenvironment that promotes
metastasis both in animal models and human cancer pa-
tients [36, 37]. The results from clinical trials indicate
that inhibitors of TGF-β signaling may enhance anti-tumor
immune responses in patients [38], causing us to wonder
whether naringenin could also exhibit anti-tumor immune
responses in 4T1/TGF-β1 tumor-bearing mice by reducing
TGF-β1 production. As expected, tumor-derived TGF-β1
established a systemic immunosuppressive environment
that was represented by an increase of the CD4+Gr11b+ T-
cell population and a decrease of the activated subpopula-
tion of CD4+CD44+CD62L– T cells in lungs and spleens
and CD8+IFNγ+ T cells in spleens (Fig. 4a–c). In addition,
the mRNA levels of effector molecules such as IFNγ
and granzyme-B in the lungs were reduced after tumor
injection (P <0.001) (Fig. 4d). Naringenin treatment
effectively reversed the tumor-mediated immunosup-
pressive environment; its effect was comparable with
that of 1D11 treatment (Fig. 4a–d).
To further ascertain whether the enhanced T-cell ac-
tivity after naringenin treatment facilitates its inhibitory
effect on breast cancer pulmonary metastasis, we trans-
ferred the T cells from 4T1/TGF-β1 tumor-bearing mice
into nude mice along with 4T1/TGF-β1 tumor cells.
Compared with nude mice with T cells transferred from
normal mice (Control) and from the mice without narin-
genin treatment (CMCNa), the nude mice that received
T cells from mice with naringenin treatment showed a
decreased incidence of pulmonary metastasis (100 %
(6/6) vs 83 % (5/6) vs 50 % (3/6) in dissected lungs;
and 100 % (6/6) vs 67 % (4/6) vs 33 % (2/6) in whole
bodies) (Fig. 4e–g). In addition, one of the nude mice
transferred with T cells from mice without naringenin
treatment showed expanded whole body metastases
besides lung metastases (Fig. 4f ).
Naringenin reduces TGF-β1 secretion and invasion of 4T1
cells in vitro
Overexpression of Tgf-β1 in 4T1 cells promoted pul-
monary metastasis, and naringenin inhibited pulmonary
metastasis by decreasing TGF-β1 levels. We then asked
whether naringenin inhibited the secretion of TGF-β1
from 4T1/TGF-β1 cells. Compared with 4T1/RFP cells,
the overexpression of Tgf-β1 in 4T1/TGF-β1 cells led to
a significant increase of secreted TGF-β1 (2.3-fold differ-
ence, P = 0.02) and promoted invasion of the cells
(Fig. 5a, b). Knockdown of Tgf-β1 by TGF-β1 specific
small interfering RNA (siRNA) and neutralization of
TGF-β1 by 1D11 antibody in 4T1/RFP cells showed an
inhibitory effect on the invasion and TGF-β1 secretion
of tumor cells (siRNA vs control, 0.46-fold difference,
P = 0.01; 1D11 vs control, 0.31-fold difference, P = 0.003)
(Fig. 5a, b and Additional file 6: Figure S4A, B).
Naringenin treatment resulted in decreased TGF-β1
secretion (in 4T1/RFP cells, 0.64-fold difference, P = 0.04;
in 4T1/TGF-β1 cells, 0.69-fold difference, P = 0.05) and
cell invasion in both 4T1/RFP and 4T1/TGF-β1 cells. The
combination of naringenin and TGF-β1 specific siRNA
showed no difference in TGF-β1 secretion (P = 0.18)
and tumor cell invasion (Additional file 6: Figure S4A, B)
from each agent alone. These in vitro results provided
(See figure on previous page.)
Fig. 1 TGF-β1 overproduction in 4T1 cells promotes pulmonary metastasis. a Tgf-β1 mRNA relative expression level in cultured 4T1/RFP cells and
4T1/TGF-β1 cells, P <0.001. b Intracellular and secreted TGF-β1 protein concentration in cultured 4T1/RFP cells and 4T1/TGF-β1 cells. c Migration
and invasion of cultured 4T1/RFP cells and 4T1/TGF-β1 cells treated with 1D11 were observed under the fluorescent microscopy. Migration and
invasion were detected by wound healing and transwell respectively after cells were treated with 1D11 for 48 hours (left). The invaded 4T1/RFP
and 4T1/TGF-β1 cells treated with 1D11 were dissolved in DMSO and OD590 values were determined using the multimode reader (right).
d Bioluminescence imaging of 4T1 breast cancer lung metastasis on day 28 in vivo using IVIS, P = 0.023. (Median ± IQ range.) e Bioluminescence
imaging of breast cancer metastasis in the dissected lungs. P = 0.006. (Median ± IQ range.) f Histological imaging of lung tissue sections of mice
bearing 4T1/RFP tumors or 4T1/TGF-β1 tumors on day 28. Hematoxylin and eosin staining was carried out in 5 μm sections of paraffin-embedded
lung tissues. Black arrow indicates metastatic tumor. g Primary tumor weight of mice bearing 4T1/RFP tumor or 4T1/TGF-β1 tumor on day 28. h Weights
of tumor burden in lungs of mice bearing 4T1/RFP tumor and 4T1/TGF-β1 tumor on day 28. Results are representative of at least three experiments.
*P <0.05, **P <0.01, ***P <0.001. Error bars indicate SE. TGF transforming growth factor
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complementary data to confirm that naringenin sup-
pressed the invasion of breast cancer cells by reducing
autocrine TGF-β1 signaling from the tumor cells.
TGF-β1 can convert lymphatic T cells to Tregs. We
next investigated whether naringenin could suppress the
conversion of Tregs in vitro. In agreement with the in vivo
data, the supernatants from cells treated with naringenin
or 1D11 showed a suppression of Treg conversion activity
(Fig. 5c and Additional file 6: Figure S4C). TGF-β1
siRNA also inhibited the conversion of Tregs in 4T1/RFP
cells (0.66-fold difference, P = 0.04) (Additional file 6:
Figure S4C). Compared with that of control, the
supernatant of 4T1/RFP cells treated with TGF-β1
siRNA or 4T1/TGF-β1 cells treated with naringenin,
which contained a lower concentration of TGF-β1, showed
a reduced capacity to induce the expression of MMP2
and MMP9 mRNA in 4T1 cells (Additional file 6:
Figure S4D, E). Interestingly, although both naringenin
and 1D11 reduced TGF-β1 secretion, 1D11 did not change
the intracellular TGF-β1 concentration while naringenin
Fig. 2 Naringenin (Nar) prevents pulmonary metastasis derived from the primary breast tumor. a Bioluminescence imaging of pulmonary
metastasis in vivo. Mice bearing 4T1 tumor were treated with Nar or 1D11 for 34 days and then were imaged with bags to avoid the
bioluminescence from primary tumor. b Bioluminescent photons of the pulmonary area from the mice treated with Nar or 1D11 antibodies for
34 days measured using the IVIS system (median ± IQ range). c Survival of mice bearing 4T1/RFP tumor (left) or 4T1/TGF-β1 (right) tumor after
treatment with Nar or 1D11 antibodies. d TGF-β1 concentration in lung homogenates and serum. Results are representative of three experiments.
*P <0.05, **P <0.01, ***P <0.001. Error bars indicate SE. TGF transforming growth factor
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resulted in an intracellular accumulation of TGF-β1
(Fig. 5b, d). The levels of secreted and intracellular TGF-β1
in different human breast cancer cell lines and 293T and
MDCK cells treated with naringenin for 48 hours were also
detected. The results showed that naringenin significantly
decreased TGF-β1 secretion and increased intracellular
Fig. 3 Naringenin (Nar) reduces the population of Tregs in spleens and lungs. a Flow cytometry analysis of the percentage of CD4+CD25+Foxp3+
cells (Tregs) in lymphocytes purified from spleen and lung tissues. b Flow cytometry analysis of the percentage of CD103+CD4+ Foxp3+ cells in
lymphocytes purified from spleen and lung tissues. Column charts show the mean percentage obtained from three experiments. Percentage
gated cells are shown. Results are representative of three or four experiments. *P <0.05, **P <0.01, ***P <0.001. Error bars indicate SE. CMCNa
sodium carboxyl methyl cellulose, PBS phosphate-buffered saline, TGF transforming growth factor
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Fig. 4 (See legend on next page.)
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TGF-β1 concentrations in multiple human breast can-
cer cells, including MCF7, MDA-MB-231, MDA-MB-
436, and MDA-MB-468 cells, but not in 293T and
MDCK cells (Additional file 7: Figure S5).
Naringenin prevents TGF-β1 release
1D11 treatment had no effect on the intracellular TGF-
β1 concentration in 4T1 cells, suggesting that naringenin
may have a different mechanism of action from siRNA
or 1D11 in reducing the secretion of TGF-β1. Thus, we
investigated the mechanisms underlying the inhibitory
effect of naringenin on TGF-β1 secretion, which involve
a series of controlled processes, including transcription,
post transcription, and post translation. We surprisingly
found that the transcription of Tgf-β1 was not influ-
enced by naringenin treatment (Additional file 8:
Figure S6B). The post-transcriptional regulation of Tgf-β1
was also investigated using actinomycin D, which blocks
(See figure on previous page.)
Fig. 4 Naringenin (Nar) improves the immune activities of T cells. a Flow cytometry analysis of T-cell activation marker expressed CD4+CD44+CD62L–
cells in lymphocytes purified from spleen and lung tissues. b Flow cytometry analysis of the percentage of Gr-1+CD11b+ cells (MDSC) in leukocytes
purified from spleen and lung tissues. Data are from three mice per group. c Analysis of IFNγ+ specific CD8+ cell percentage in lymphocytes purified
from the spleen of mice bearing 4T1/RFP tumors or 4T1/TGF-β1 tumors. d Analysis of the mRNA level of IFNγ and granzyme-B (Gran B) in lung samples
of mice bearing 4T1/RFP tumors or 4T1/TGF-β1 tumors. Data are from three experiments. *P <0.05, **P <0.01, ***P <0.001. Error bars indicate
SE. e, f Bioluminescence imaging of the dissected lungs e and whole bodies f of nude mice after transferring T cells from Balb/c mice
treated with or without naringenin for 28 days using the IVIS system (n = 6). g Incidence of pulmonary metastasis of the dissected lungs
and whole bodies (n = 6). CMCNa sodium carboxyl methyl cellulose, IFN interferon, TGF transforming growth factor
Fig. 5 Naringenin (Nar) inhibits TGF-β1 secretion and the invasion of 4T1 cells in vitro. a Invasion of cultured 4T1/RFP cells (upper) and 4T1/TGF-β1 cells
(lower) after treatment with 100 μM of Nar or 5 μg/ml of 1D11 for 48 hours. The transwell cells were stained and imaged under microscopy
(100×) following fixation (left). The stained cells were dissolved using DMSO and OD590 values were determined using the multimode reader (right).
b Secreted TGF-β1 concentration in supernatant from 4T1/RFP cells and 4T1/TGF-β1 cells after treatment with Nar or 1D11 for 48 hours. c Flow
cytometry analysis of the percentage of Tregs induced by the cell supernatants. Percentage gated cells are shown (upper). Column charts show
the mean percentage obtained from three experiments (lower). d TGF-β1 concentration in 4T1/RFP cells and 4T1/TGF-β1 cells after treatment with Nar
or 1D11 for 48 hours. *P <0.05, **P <0.01, ***P <0.001. Error bars indicate SE. TGF transforming growth factor, Treg regulatory T cell
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mRNA synthesis, in the presence or absence of narin-
genin. Naringenin did not affect the decay of Tgf-β1
mRNA in the presence of actinomycin D (P = 0.65)
(shown in Additional file 6: Figure S4C).
Next, we tested whether naringenin regulates the
translation of TGF-β1 using cycloheximide (CHX) to
block protein synthesis in 4T1 cells. CHX treatment in-
duced a decrease of secreted TGF-β1 and intracellular
TGF-β1 (P <0.05) (Additional file 9: Figure S7). Naringenin
treatment showed that the time-dependent increase of
intracellular TGF-β1 was in parallel to a gradual decrease
of secreted TGF-β1 into the media (naringenin vs control,
from 24 to 48 hours detected, P <0.05) (Fig. 6a and
Additional file 8: Figure S6). The effects of naringenin
on released TGF-β1 and intracellular TGF-β1 were
still observed in the presence of CHX (P = 0.04 for
intracellular TGF-β1; P = 0.05 for released TGF-β1
after 48 hours of treatment) (Fig. 6b). Flow cytometry
analysis of intracellular TGF-β1 further confirmed that
naringenin induced an accumulation of intracellular TGF-
β1 in the presence or absence of CHX (in the absence of
CHX, 1.4-fold difference, P = 0.02; in the presence of
CHX, 1.7-fold difference, P = 0.04) (Fig. 6c).
TGF-β proteins, synthesized as precursor proteins, are
cleaved in the ER and then transported through the
TGN to the cell surface for release or to the lysosome
for degradation. We therefore hypothesized that narin-
genin might reduce lysosomal degradation of TGF-β1,
resulting in the observed cellular accumulation. To
address this hypothesis, we utilized a specific lysosome in-
hibitor, bafilomycin A1, which prevents protein degrad-
ation by raising lysosomal pH. Interestingly, bafilomycin
A1 treatment significantly increased the intracellular accu-
mulation of TGF-β1 while also increasing extracellular
TGF-β1 release (intracellular, twofold difference, P = 0.01;
extracellular, 1.6-fold difference, P = 0.02), indicating that
more TGF-β1 can be released by cells after blocking lyso-
somal degradation (Fig. 6d, e). In contrast to bafilomycin
Fig. 6 Naringenin (Nar) reduces the release of TGF-β1. a, b Changes of cellular and secreted TGF-β1 in 4T1 cells after treatment with Nar in the
absence of CHX (a Nar to untreated Control) or the presence of CHX (b Nar to CHX treatment) over time. c Flow cytometry analysis of the cellular
TGF-β1 level in 4T1 cells after treatment with Nar, CHX, or the combination of Nar and CHX for 24 hours. d Western blot analysis of the cellular TGF-β1
level in 4T1 cells after treatment with Nar, Bafilomycin A (Baf), or the combination of Nar and Baf for 24 hours. e Intracellular and secreted TGF-β1
concentrations of 4T1 cells treated with Nar, Baf, or the combination of Nar with Baf for 24 hours were measured by ELISA. *P <0.05, **P <0.01,
***P <0.001. Error bars indicate SE. CHX cycloheximide, GAPDH glyceraldehyde 3-phosphate dehydrogenase, TGF transforming growth factor
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A1 treatment, naringenin treatment decreased the extra-
cellular release of TGF-β1 even in the presence of bafilo-
mycin A1 (0.57-fold difference, P = 0.02) (Fig. 6d, e),
suggesting that the lysosomal degradation process does
not involve in the effects of naringenin.
Naringenin inhibits protein kinase C activation and
trafficking of TGF-β1
Previous studies have demonstrated that the protein kin-
ase C (PKC) family of kinases is involved in the trans-
port and sorting of many proteins from the TGN to cell
membranes and organelles [39], prompting us to address
whether PKC is involved in the trafficking of TGF-β1.
To test this hypothesis, we first investigated the expres-
sion of 11 members of the PKC family in 4T1/RFP cells
and 4T1/TGF-β1 cells (Additional file 10: Table S2). The
results showed that Tgf-β1 expression positively correlated
with PRKCE (3.1-fold difference, P = 0.008) and PRKCZ
mRNAs (1.5-fold difference, P = 0.04), suggesting that
PKC-ε and PKC-ζ proteins might be involved in the trans-
port of TGF-β1. Silencing PKC-ε and PKC-ζ in 4T1 cells
using the respective siRNAs showed a decrease of Tgf-β1
mRNA expression (PKC-ε silencing, 0.57-fold difference,
P = 0.04; PKC-ζ silencing, 0.63-fold difference, P = 0.05)
(Fig. 7a). These results suggest that TGF-β1 and PKC-ε or
PKC-ζ may work in a positive feedback loop. To further
investigate the relationship between TGF-β1 and PKC-ε
or PKC-ζ, we determined the production of TGF-β1 pro-
tein in 4T1 cells after silencing PKC-ε or PKC-ζ; mean-
while, the phosphorylation status of PKC-ε and PKC-ζ
was also detected. Compared with untreated cells, PKC-ε
and PKC-ζ siRNA-treated cells showed reduced expres-
sions of the targeted genes, both the total protein levels
and the phosphorylation levels (Fig. 7b); correspondingly,
the amount of TGF-β1 released from the cells was signifi-
cantly reduced (PKC-ε silencing, 0.62-fold difference, P =
0.008; PKC-ζ silencing, 0.76-fold difference, P = 0.038), but
resulted in an accumulation of cellular TGF-β1 (PKC-ε
Fig. 7 Naringenin (Nar) inhibits the activation of PKC-ε and PKC-ζ. a Analysis of the relative mRNA level of PRKCE, PRKCZ, and Tgf-β1 in 4T1 cells
treated with 100 μM of Nar for 24 hours with or without transfection using the siRNAs of PRKCE or PRKCZ. b Western blot analysis of PKC-ε, p-PKC-ε,
PKC-ζ, and p-PKC-ζ expression in 4T1 cells treated with Nar for 48 hours with or without transfection using siRNAs of PRKCE or PRKCZ. Imaging of
western blot bands (left) and quantitative data of protein expression relative to GAPDH from three repeats (right). c Cellular and secreted TGF-
β1 concentrations of 4T1 cells treated with Nar for 48 hours with or without transfection using the siRNAs of PRKCE or PRKCZ. d Confocal imaging of
TGF-β1 and TGN in 4T1 cells treated with Nar, phorbol 12-myristate 13-acetate (PMA), calphostin C (Cal), the combination of Nar and PMA, or Nar and
Cal for 48 hours. e, f Cellular e and secreted f TGF-β1 concentrations of 4T1 cells treated with Nar, PMA, Cal, the combination of Nar and PMA, or Nar
and Cal for 48 hours. *P <0.05, **P <0.01, ***P <0.001. Error bars indicate SE. GAPDH glyceraldehyde 3-phosphate dehydrogenase, PKC protein kinase C,
TGF transforming growth factor, PMA phorbol 12-myristate 13-acetate
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silencing, 1.57-fold difference, P = 0.015; PKC-ζ silencing,
1.54-fold difference, P = 0.04) (Fig. 7c). Silencing PKC-ε or
PKC-ζ with siRNA had similar results to naringenin treat-
ment, which decreased secretion of TGF-β1 (0.64-fold dif-
ference, P = 0.006) while increasing intracellular levels of
TGF-β1 (1.54-fold difference, P = 0.012) (Fig. 7c). However,
naringenin treatment had no effect on the mRNA and pro-
tein expression of PKC-ε or PKC-ζ, but did inhibit
their phosphorylation (Fig. 7a, b). The combination of
naringenin and siRNAs targeting PKC-ε or PKC-ζ ex-
hibited a synergistic effect on decreasing TGF-β1 se-
cretion (Fig. 7c). Taken together, our results suggest
that both PKC-ε and PKC-ζ regulate TGF-β1 traffick-
ing, and that naringenin inhibits the activation of
PKC-ε and PKC-ζ, which prevents TGF-β1 secretion.
Golgi-bound PKC has been shown to have a crucial
impact on vesicle formation at the TGN [39]. Therefore,
we sought to address whether the naringenin-mediated
cellular accumulation of TGF-β1 is due to blocking the
transport of TGF-β1 from the TGN to the plasma mem-
brane. We used phorbol 12-myristate 13-acetate (PMA)
to activate PKC in 4T1 cells, and observed the distribu-
tion of the TGN and TGF-β1 by immunofluorescence.
Compared with untreated cells, PMA-treated cells had
an increased density of TGN in the vicinity of the
plasma membrane with a more dispersed cytoplasmic
distribution and lower fluorescence intensity of TGF-β1,
indicating that more TGF-β1 was released from the cells
(Fig. 7d). Indeed, we found that PMA treatment resulted
in a 0.57-fold decrease of TGF-β1 concentration in the
cells and a 1.77-fold increase of TGF-β1 concentration
in the culture media (Fig. 7e, f ). The addition of calphos-
tin C, a specific inhibitor of PKC, resulted in an in-
creased density of the TGN and TGF-β1-containing
vesicles around the nucleus with brighter fluorescence
(Fig. 7d), along with more cellular accumulation (2.5-fold
difference, P = 0.01) and less release of TGF-β1 (0.42-fold
difference, P = 0.02) (Fig. 7e, f ). Cells treated with narin-
genin showed similar responses to the addition of cal-
phostin C (Fig. 7d–f ), suggesting that naringenin is a
potential inhibitor of PKC. Furthermore, addition of
naringenin to PMA-treated cells partially reversed the
effects of PMA, but naringenin had no effect on cal-
phostin C-treated cells (Fig. 7d–f ). Taken together, nar-
ingenin reduced TGF-β1 secretion by blocking its cellular
transport through inhibition of PKC rather than promot-
ing its degradation and/or inhibiting its expression.
Discussion
In this study, we demonstrated that TGF-β1 derived from
breast cancer cells promotes tumor cell metastasis through
immune suppression. Similar to 1D11 antibody, which in-
creased the population of anti-tumor effector T cells, nar-
ingenin inhibited breast cancer metastasis by blocking
TGF-β1 secretion both in vitro and in vivo. Interestingly,
as opposed to 1D11, which had no effect on the intracellu-
lar TGF-β1 concentration, naringenin induced an accumu-
lation of TGF-β1 in 4T1 murine breast cancer cells as well
as multiple human breast cancer cells (Additional file 7:
Figure S5). Further investigations into the mechanism re-
vealed that naringenin blocked the intracellular trafficking
of TGF-β1 via inhibiting PKC-ε and PKC-ζ phosphoryl-
ation rather than modulating the degradation or expression
of TGF-β1. This may provide a novel therapeutic strategy
toward targeting the TGF-β signaling pathway.
Silencing PKC-ε or PKC-ζ in invasive breast cancer cells
inhibited TGF-β1 release, suggesting that the trafficking of
TGF-β1 from the TGN compartment to the cell
membrane is mediated by PKC proteins. Similar to PKC
inhibitor treatment, naringenin treatment resulted in an
increased colocalization of TGF-β1 and the TGN in
breast cancer cells. These experiments demonstrate that
naringenin prevents TGF-β1 transport from the TGN by
inhibiting PKC activation (Fig. 7 and Additional file 11:
Figure S8). Intriguingly, naringenin showed no effect on
TGF-β1 secretion in normal mice [26] or normal cells
(Additional file 7: Figure S5), which suggests that narin-
genin may only have this activity in cells expressing abnor-
mally high TGF-β1 levels. Naringenin reduced TGF-β1
secretion by inhibiting PKC activity, which is a different
mechanism of action from the current inhibitors of TGF-
β1 signaling, such as TGF-β1 antibodies and antagonists
of its receptors, which directly target the pathway. These
inhibitors have been shown to have undesired systemic
side effects due to the multiple physiological functions of
TGF-β1. PKC is a critical regulator of the trafficking re-
quired for cytokine secretion; therefore, targeting PKC may
provide a previously unidentified avenue for designing
therapeutic interventions for multiple cytokine disorders.
Flavonoids have been reported to modulate Tgf-β1 ex-
pression and/or secretion in different contexts. Quer-
cetin has been shown to induce large amounts of TGF-
β1 secretion in leukemic blasts, resulting in an inhibition
of acute myeloid leukaemia (AML) and acute lymphoid
leukemia (ALL) blast growth [40]. However, a recent
study demonstrated that quercetin alleviated bile duct
ligation-induced Tgf-β1 expression in rats [41]. Similarly,
dihydromyricetin was shown to inhibit proliferation of
Hepa l-6 cells by downregulating Tgf-β1 expression
[42]. These differences in the regulation of TGF-β1
by flavonoid compounds may be due to their differ-
ent chemical structures. Future studies will need to
investigate the mechanisms by which different flavon-
oid compounds selectively regulate TGF-β1 signaling.
TGF-β1 overexpression, which is tumor suppressive in
the primary lesion yet promotes metastatic dissemin-
ation, has been found in a majority of breast cancer pa-
tients [43]. These duel functions of TGF-β1 in cancer
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development have led to the potential of combining
TGF-β1 inhibitors with radiation or peptide vaccine for
cancer therapies [44, 45]. We have previously found that
naringenin not only downregulated Smad3 expression
and phosphorylation [27, 46] but also inhibited TGF-β1
ligand/receptor binding [47]. In this study, we further
found that naringenin prevented TGF-β1 secretion from
breast cancer cells by inhibiting PKC phosphorylation.
The extensive involvement of naringenin in the TGF-β1
pathway makes it a potentially more potent antagonist
of TGF-β signaling than other PKC inhibitors or the
TGF-β1 antibody. Given that naringenin can modulate
the intracellular trafficking of TGF-β1, we expect that
naringenin could effectively prevent tumor metastasis,
making it an attractive candidate to be used in combin-
ation with other anti-cancer therapies [48].
Conclusions
We present data demonstrating that naringenin represents
an attractive therapeutic candidate for the prevention of
breast cancer metastasis, although it has no benefit for the
primary tumor. The combination of naringenin with radi-
ation or peptide vaccine might provide new therapeutic
strategies to treat cancer progression and metastasis.
Ethics approval and consent to participate
All animal protocols used for this study were approved
by the Institutional Animal Care and Use Committee.
Additional files
Additional file 1: Presents the supplementary methods. (DOC 54 kb)
Additional file 2: Figure S1. Showing the secreted TGF-β1 concentration
and OD590 values of transwell cells in different human breast cancer cells.
A Secreted TGF-β1 concentrations in different cells were measured by ELISA
after cultured for 48 hours. B Invasion of transwell cells stained and
dissolved using DMSO and OD590 values determined using the multimode
reader. Error bars indicate SE. (TIF 155 kb)
Additional file 3: Figure S2. Showing the effect of naringenin (Nar) on
the growth of primary 4T1 tumors. A Bioluminescence imaging of pulmonary
metastasis in vivo. Mice bearing 4T1 tumors were treated with Nar or 1D11
24 days and then were imaged with bags to avoid the bioluminescence
from primary tumor. B Bioluminescence imaging of primary tumors in vivo.
Mice bearing tumors were treated with Nar or 1D11 for 24 and 34 days and
then were imaged the bioluminescence using the IVIS system. C Volume of
primary breast tumor measured by calipers. Tumor volumes were measured
by calipers after tumor injection from 10 to 34 days. Error bars indicate SE.
(TIF 1908 kb)
Additional file 4: Table S1. Presenting the incidence of pulmonary
metastasis (mice with metastasis/total mice). Tumor-bearing mice treated
with naringenin or 1D11 were imaged on day 24 using bags to avoid the
bioluminescence from primary tumor. The mice with pulmonary metastases
were numbered based on the bioluminescence signal. (TIF 26 kb)
Additional file 5: Figure S3. Showing the effects of naringenin (Nar)
on the expression of TGF-β1 and Foxp3 in vivo. A, B TGF-β1 concentrations
in the homogenates of tumor, spleen, lung, and serum from mice
after treatment for 14 and 28 days. Mice bearing 4T1/RFP tumors or 4T1/TGF-
β1 tumors were treated with Nar for 14 and 28 days. The tissues were
homogenated and collected for TGF-β1 detection by ELISA kit. C
Immunohistochemical analysis of TGF-β1 expression and location in
lung tissue sections of mice bearing 4T1/RFP tumors or 4T1/TGF-β1
tumors after treatment with Nar for 14 and 28 days. D Expression of
TGF-β1 and Foxp3 proteins in lung tissues of mice bearing 4T1/RFP
tumors or 4T1/TGF-β1 tumors after treatment with Nar for 14 and
28 days by western blot analysis. *P <0.05, **P <0.01, ***P <0.001.
Error bars indicate SE. (TIF 1071 kb)
Additional file 6: Figure S4. Showing the effects of naringenin (Nar)
on the invasion of and the TGF-β1secretion of 4T1 cells. A Invasion of
cultured 4T1/RFP cells, 4T1/TGF-β1 cells, and 4T1 cells knocked down by
TGF-β1siRNAwith or without Nar treatment for 48 hours (upper). Invasion
of 4T1 cells cultured with the individual supernatants from the upper cells
for 48 hours (lower). B Measurement of the secreted TGF-β1 concentration
in supernatants from 4T1/RFP cells, 4T1/TGF-β1 cells, and 4T1 cells knocked
down by TGF-β1 siRNA with or without Nar treatment for 48 hours. C. Flow
cytometry analysis of the percentage of Tregs induced by the supernatants.
The lymphocytes were purified from spleen tissues of 8-week-old mice. The
supernatants from 4T1/RFP cells, 4T1/TGF-β1 cells, and 4T1 cells knocked
down by TGF-β1 siRNA with or without Nar treatment for 48 hours were
used to culture the lymphocytes which activated with monoclonal antibodies
against CD3/CD28. After 72 hours of incubation, the lymphocytes were
collected and stained with CD4+CD25+Foxp3+ antibodies for flow cytometry
analysis. D, E Analysis of mRNA levels of MMP2 and MMP9 in 4T1 cells treated
with the supernatants from 4T1/RFP cells, 4T1/TGF-β1 cells, and 4T1 cells
knocked down by TGF-β1 siRNA with or without Nar treatment for 48 hours.
*P <0.05, **P <0.01, ***P <0.001. Error bars indicate SE. (TIF 4025 kb)
Additional file 7: Figure S5. Showing the effects of naringenin (Nar)
on the cellular and secreted TGF-β1 concentration in different cell lines.
A Cellular TGF-β1 concentrations in cultured cells after the treatment of
100 μM naringenin for 48 hours. B Secreted TGF-β1 concentrations in the
media of different cultured cells with 100 μM naringenin treatment for
48 hours. The levels of TGF-β1 concentrations were determined by
ELISA. Data are from at least three independent experiments. *P <0.05,
**P <0.01, ***P <0.001. Error bars indicate SE. (TIF 128 kb)
Additional file 8: Figure S6. Showing the effects of naringenin (Nar)
on the transcription and decay of Tgf-β1 mRNA. A Secreted TGF-β1
concentrations in the media of cultured 4T1 cells with naringenin treatment
for different times. B Analysis of mRNA levels of Tgf-β1 in cultured 4T1 cells
with or without naringenin treatment for 24 and 48 hours. C Analysis of the
stability of Tgf-β1 mRNA in 4T1 cells after naringenin treatment. Cells
were pretreated with 100 μM naringenin or diluent for 2 hours, followed by
addition of 10 μg/ml actinomycin D to inhibit the synthesis of new
RNA. The levels of remained TGF-β1 mRNA were determined by
qPCR. Data are from at least three independent experiments. *P <0.05,
**P <0.01, ***P <0.001. Error bars indicate SE. (TIF 139 kb)
Additional file 9: Figure S7. Showing the changed percentages of
the cellular and the secreted TGF-β1 of 4T1 cells after treatment with
10 μM cycloheximide (CHX treatment to untreated control) over time.
The intracellular and the secreted TGF-β1 proteins were analyzed
using ELISA kit. (TIF 48 kb)
Additional file 10: Table S2. Presenting the mRNA expression copies
of PKC family genes in 4T1/RFP cells and 4T1/TGF-β1 cells. Total RNA
was extracted and real-time qPCR was performed for detection the
relative mRNA expression copies of PKC to 106 of GAPDH copies.
*P <0.05, **P <0.01. (TIF 36 kb)
Additional file 11: Figure S8. Showing western blot analysis of the
expression and activation of PKC proteins in lung tissues of mice bearing
4T1/RFP tumors or 4T1/TGF-β1 tumors after naringenin (Nar) administration
for 28 days (detailed procedure is described in Methods). (TIF 63 kb)
Abbreviations
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